Overview

Safety Study of Lopinavir/Ritonavir With Raltegravir in HIV-infected Patients

Status:
Completed
Trial end date:
2010-06-01
Target enrollment:
Participant gender:
Summary
A single center, open label, 48-week study of lopinavir/ritonavir in combination with raltegravir. 30 patients, both naïve and experienced, will be enrolled. 15 treatment naïve patients and 15 treatment experienced patients enrolled
Phase:
Phase 4
Details
Lead Sponsor:
Saint Michael's Medical Center
Collaborator:
Abbott
Treatments:
Lopinavir
Raltegravir Potassium
Ritonavir